Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.
暂无分享,去创建一个
D. Bajorin | H. Nishiyama | A. Balar | A. Kamat | P. Grivas | J. Boormans | H. Seo | B. Konety | E. Uchio | G. Kulkarni | M. Roumiguié | J. Zambon | K. Nam | E. Singer | E. Kapadia | L. Krieger | Ronald de Wit | Ronald de Wit